SRR10899986
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_SURFACE+0.300
- APOPTOSIS+0.300
- COAGULATION+0.300
- COMPLEMENT+0.300
- E2F_TARGETS+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- BILE_ACID_METABOLISM-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- FATTY_ACID_METABOLISM-0.200
- GLYCOLYSIS-0.200
- HYPOXIA-0.200
- PEROXISOME-0.200
- ADIPOGENESIS-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2304 | Med | Medulloblastoma | 0.814 |
| 2 | SRR8613717 | — | D | 0.793 |
| 3 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.791 |
| 4 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.784 |
| 5 | MNG215 | — | — | 0.776 |
| 6 | MNG523 | — | — | 0.774 |
| 7 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.773 |
| 8 | s0122319 | — | — | 0.770 |
| 9 | TCGA-OR-A5J8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.768 |
| 10 | TCGA-DK-A3IU-01A-11R-A20F-07 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |